Search Results for:
-
Clinic Roundup
Incyte Corp., of Wilmington, Del., reported at the European Hematology Association meeting results from two ongoing clinical trials of Jakafi (ruxolitinib), an oral JAK1 and JAK2 inhibitor that is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MFBioWorld Today | Tuesday, June 18, 2013 -
Elan Up for Sale as Investors Reject Management, Royalty
Although a subcutaneous formulation of the drug is still undergoing clinical trials expectations are low, as the intravenous version failed in a pivotal Phase III programBy Cormac Sheridan | BioWorld Today | Tuesday, June 18, 2013 -
Other News To Note
Wuxi PharmaTech Inc., also of Shanghai, will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, preclinical development and clinical trials...The €6 million (US$8 million) grant was provided to the Cardimmun consortium, consisting of Athera, Leiden University Medical Center, Turku PET Center, Clinical Trial Consultants and Smerud Medical ResearchBioWorld Today | Tuesday, June 18, 2013 -
Conatus Pharma Seeks $69M for Liver Drug Emricasan
After four years of development, in 2011 Conatus terminated a Phase II trial of the compound in hepatitis C patients – and, subsequently, its development – following reports of laboratory abnormalities and adverse events in a subset of clinical trial participantsBy Marie Powers | BioWorld Today | Monday, June 17, 2013 -
X01 Cracks Coagulation Conundrum, Raises $11M
Essentially, the product has already had a long-term, high-dose clinical trial in one patientBy Catherine Shaffer | BioWorld Today | Monday, June 17, 2013 -
Phase I Clinical Trials Update: May 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE Novan Therapeutics Inc. (Durham, N.C.) SB204 Nitric oxide-releasing compound Acne Reduced colonization of skin in a Phase I trial 5/31/13 Soligenix Inc. (Princeton, N.J.) SGX203 Oral beclomethasone 17, 21-diproprionate Pediatric Crohn's disease Began its first trial 5/16/13 Xenetic Biosciences plc (London) Myeloxen Vaccine based on the Imuxen liposomal technology Multiple sclerosis Completed the Phase I safety study 5/13BioWorld Insight | Monday, June 17, 2013 -
Phase III Clinical Trials Update: May 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and Sanofi SA (Paris) Sarilumab Fully human monoclonal antibody directed against the alpha subunit of the IL-6 receptor complex Moderate to severe rheumatoid arthritis Enrolled their first patients in Phase III trials 5/16/13 Xenoport Inc. (Santa Clara, Calif.) Arbaclofen placarbil A prodrug of the R-isomer of baclofen Spasticity due to multiple sclerosis Terminated theBioWorld Insight | Monday, June 17, 2013 -
Non-U.S. Clinical Trials & Regulatory Actions: May 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE GW Pharmaceuticals plc (Porton Down, UK) Sativex Cannabinoid product Moderate to severe spasticity in multiple sclerosis Received commercial approval for Sativex in Italy 5/8/13 CANCER Aveo Pharmaceuticals Inc. (Cambridge, Mass.) and Astellas Pharma Inc. (Tokyo) Tivozanib A once-daily, VEGF receptor tyrosine kinase inhibitor Advanced renal cell carcinoma Astellas no longer intends to submit an MAA and will not fund anyBioWorld Insight | Monday, June 17, 2013 -
Word on the Street
There are a lot of situations where people use only an animal model and take a shot at a clinical trial and are disappointed after spending resources that could have been spent elsewhere." – Gene Williams, executive chairman and CEO of DART Therapeutics Inc., discussing its use of Biovista Inc.'s clinical outcomes search space technology to identify potential drug candidates for in-licensing in Duchenne's muscular dystrophy "I think the biggest challenge today for selling into BRIC for globalBioWorld Insight | Monday, June 17, 2013 -
Phase II Clinical Trials Update: May 2013
Company (Location) Product Description Indication Status Date AUTOIMMUNE Creabilis SA (Luxembourg) CT327 Topical TrkA kinase inhibitor Chronic pruritis caused by psoriasis Phase IIb data showed a statistically significant and clinically meaningful reduction in pruritus of 60 percent compared to 20 percent for those receiving placebo 5/13/13 Idera Pharmaceuticals Inc. (Cambridge, Mass.) IMO-3100 A selective antagonist of Toll-like receptors 7 and 9 Psoriasis Phase II data showed improvementsBioWorld Insight | Monday, June 17, 2013 -
Other News To Note
Specifically, the partnership will focus on clinical trials to test combinations of immunotherapies, including two investigational drugs from Immune Design's pipelineBioWorld Today | Thursday, June 13, 2013 -
Clinic Roundup
The company recently launched the Crohn's disease clinical trial and is actively recruiting participants with moderate to severe diseaseBioWorld Today | Thursday, June 13, 2013 -
PRISM Banks $15M to Fund Cancer Drug R&D for Fibrosis
The compound is currently undergoing early stage clinical trials for the treatment of leukemia and solid tumor cancer, with rights to all oncology applications licensed to its partner, Eisai Co...And although full terms of the Series C funding round were not disclosed, they did include the hitting of milestones on the fibrosis clinical trial, according to PRISM Pharma CFO, Dai TakeharaBy Dave Silver | BioWorld Today | Thursday, June 13, 2013 -
Directed Evolution Gets Gene Therapy to Where it's Needed
Schaffer said that the criteria for what constitutes a new delivery method that warrants its own safety and biodistribution data "are currently being decided at the FDA level," but that the general assumption is that in the majority of cases, vectors produced by directed evolution will need their own dataset before they are admitted into clinical trialsBy Anette Breindl | BioWorld Today | Thursday, June 13, 2013 -
Taiwan's Biopharmaceutical Market Capitalization Soars
Significantly, the same NDA dossier was used in both submissions, a milestone in the path toward clinical trial regulatory harmonization, much sought after by both Taiwanese drugmakers and global pharmaceutical companies as an easier regulatory entryway into the enormous China market...P1101 is also undergoing clinical trials for treatment of polycythemia vera, a condition when the bone marrow makes too many red blood cells, leading to CV complications such as strokesBy Dave Silver | BioWorld International | Wednesday, June 12, 2013 -
U.S. Biopharma Firms Hit by Cyber Attacks from China
These efforts may have yielded valuable data from clinical trials or drug registration applicationsBy Shannon Ellis | BioWorld International | Wednesday, June 12, 2013 -
Other News To Note
Proceeds will be used to fund clinical trials, R&D for additional alpha-1 antitrypsin (AAT) indications, expanding distribution capabilities for additional territories for marketing AAT product Glassia and for general corporate purposesBioWorld International | Wednesday, June 12, 2013 -
Agios Files for $86M IPO to Support Cancer Trials
Agios expects to begin clinical trials by the middle of 2013 for its IDH2 candidate, AG-221, and in early 2014 for its IDH1 candidate, AG-120...Agios has said it may also be possible to use metabolites as biomarkers eventually for purposes such as identifying appropriate patients for clinical trialsBy Catherine Shaffer | BioWorld Today | Wednesday, June 12, 2013 -
Competition Shaping up in U.S. Biosimilars Game
The difficulty comes in the fact that, generally, patients enroll in a clinical trial in the hope of getting access to a new or improved therapy...Momenta, of Cambridge, Mass., would like to avoid the recruitment competition of large clinical trials in its development of up to six biosimilars partnered with Baxter International IncBy Mari Serebrov | BioWorld Today | Wednesday, June 12, 2013 -
Hitting the BRIC Wall? Report Examines Overseas Challenges
China, for example, has a plan "definitely" moving ahead to introduce a fast-track approval process for new drugs that could exclude firms that have not conducted clinical trials in the country, Das told BioWorld TodayBy Randy Osborne | BioWorld Today | Wednesday, June 12, 2013
Category
Current Filters
- xclinical trials
Related Keywords
Categories
- x BioWorld Today (9778)
- x BioWorld International (1962)
- x BioWorld Insight (1209)
- x Bio Perspectives (297)
- x State of the Industry Report (131)
- x BioWorld Genomics Review (58)
- x Top 25 Drug Report (43)
- x BioWorld Snapshots (29)
- x Biotech Innovations (17)
- x Market-Leading Biotech Drugs (12)
- x RNAi Report (11)
- x BioWorld Phase III Report (7)
- x Executive Compensation Report (4)
- x Recorded (4)
- x Upcoming (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.